Psilocybin vs. MDMA for PTSD: Mechanisms and Strengths

Psilocybin vs. MDMA for PTSD

0 randomized trials

No randomized controlled trial of psilocybin for PTSD has been published. Its evidence is small open-label trials with no control group. MDMA-assisted therapy has two blinded Phase 3 trials totalling 194 randomized participants — a difference in kind, not degree.

Published PTSD trial literature, reviewed August 2026

d=0.91 / d=0.7

MDMA CAPS-5 effect sizes vs placebo across two blinded Phase 3 RCTs (Mitchell 2021, n=90; Mitchell 2023, n=104)

22

participants in the largest and first PTSD-dedicated psilocybin trial — open-label, no comparator arm (McGowan 2025)

1 Jul 2023

Australia's TGA rescheduling took effect: MDMA for PTSD, psilocybin for treatment-resistant depression only (Nutt 2024)

Published PTSD trial literature, reviewed August 2026

View as image ↗

In August 2024, the FDA declined to approve MDMA-assisted therapy for PTSD, issuing a Complete Response Letter to Lykos Therapeutics despite two completed Phase 3 trials. Psilocybin, meanwhile, was moving in the opposite direction: its first dedicated PTSD trial published in 2025, and Phase 3 programmes in depression continue to expand.

That contrast has produced a widespread but mistaken impression that the two compounds are now roughly level for PTSD. They are not. MDMA-assisted therapy has been tested against placebo in two blinded, randomized Phase 3 trials. Psilocybin has never been tested against a control group for PTSD at all: its published trials are small and open-label, the largest of them enrolling 22 participants.^[2] Those are not two points on the same scale.

What is genuinely interesting is the mechanistic difference, and what it implies about which patients each compound might suit. This article focuses on that practical question — while being explicit about which parts are measured and which are inferred. For the full psilocybin PTSD trial data, psilocybin for PTSD: what the clinical trials show covers that evidence in depth.

From 'No Eligible Trials' in 2021 to a First Trial in 2025

In 2021, Varker and colleagues published a systematic review of psychoactive drugs for PTSD, screening 2,959 records for trials of MDMA, ketamine, LSD, and psilocybin.^[3] Nine trials met inclusion criteria: five of ketamine, four of MDMA. Not one psilocybin trial qualified, because at that point none existed. Under GRADE, they rated MDMA combined with psychotherapy as "moderate" evidence — the highest rating in the review.

It is worth being precise about what that review did and didn't say, because it is frequently misquoted. It did not rate psilocybin's evidence as weak or insufficient. It had nothing to rate.

That changed in 2025. McGowan and colleagues published the first dedicated psilocybin PTSD trial: a Phase 2, nonrandomized, open-label, multicentre study.^[2] Twenty-two participants received a single 25mg dose of COMP360 synthetic psilocybin with psychological support. Mean CAPS-5 at baseline was 47.5. At week 4 the mean score had fallen 29.9 points; at week 12 it had fallen 29.5 points. There were 117 treatment-emergent adverse events across the study, no serious ones, and none that led to withdrawal.

First psilocybin PTSD trial

McGowan et al. (2025) · Journal of Psychopharmacology

Population

22 adults with PTSD across three sites (King's College London, Mount Sinai, Sunstone Therapies); 63.6% female, mean age 39.0

Intervention

Single 25mg dose of COMP360 synthetic psilocybin with psychological support, plus preparatory and integration sessions

Comparator

None — nonrandomized, open-label, single-arm

Finding

Mean CAPS-5 fell 29.9 points from a baseline of 47.5 at week 4, and 29.5 points at week 12. 117 treatment-emergent adverse events, zero serious, zero withdrawals. No response rate was reported.

preliminary The trial's primary outcome was safety and tolerability, not efficacy. With no control arm, the symptom change cannot be attributed to psilocybin: expectancy, regression to the mean, natural recovery, and the substantial therapy component are all uncontrolled. This is a signal worth pursuing, not a demonstration of efficacy.

McGowan et al., Journal of Psychopharmacology, 2025 (PMID 40883964; NCT05312151)

That 29.9-point drop looks larger than MDMA's Phase 3 numbers, and this is precisely where comparisons go wrong. MDMA's trials report how much more the drug arm improved than placebo. McGowan's trial reports how much a single group improved with no comparison at all. In MAPP2, the placebo-plus-therapy arm improved by 14.8 CAPS-5 points on its own — a reminder of how much movement occurs without an active drug in these intensive therapy protocols.^[6]

A 2025 meta-analysis by Bahji and colleagues pooled 18 studies across four psychedelic-assisted therapies for depression, anxiety, and PTSD.^[1] Its headline pooled effects were for depression symptoms in a transdiagnostic population: psilocybin g=-1.92 (95% CI -2.73 to -1.11) and MDMA g=-0.71 (95% CI -1.39 to -0.03). It did not establish that the two compounds perform equivalently on PTSD symptoms, and the authors rated overall evidence certainty as low to very low, citing small samples, blinding failures, heterogeneity, and publication bias. It is a useful map of the field, not a verdict on which compound treats PTSD better.

Evidence Position

1. Cell & receptor studiescompleted

   5-HT2A agonism and downstream plasticity signalling well characterised (Choi 2024)

2. Animal studiescompleted

   Fear extinction and plasticity effects documented in rodent models

3. Case reports & adjacent populationscompleted

   Open-label psilocybin-assisted psychotherapy in traumatized AIDS survivors reduced PTSD symptoms and attachment anxiety (Khan 2022)

4. Small open-label trialscurrent

   Small uncontrolled trials only. The largest and first PTSD-dedicated one enrolled 22 participants, with a qualitative sub-study of that same cohort (McGowan 2025; Modlin 2025)

5. Randomized controlled trialmissing

   None published for psilocybin in PTSD — this is the step the field has not yet taken

6. Meta-analysis of PTSD trialsmissing

   Not possible: uncontrolled trials cannot be pooled into an effect estimate

Psilocybin for PTSD has strong mechanistic groundwork and small uncontrolled human trials. MDMA sits two full rungs higher, with replicated placebo-controlled Phase 3 data. The gap is not a matter of degree — psilocybin has not yet cleared the randomized-controlled-trial step that MDMA cleared twice.

Assessment based on published PTSD-specific trials through August 2026

What MDMA Does: Fear Reduction and the Therapeutic Window

MDMA is not a classical psychedelic. It does not act primarily at the 5-HT2A receptor that psilocybin targets. Instead it causes a large release of serotonin, dopamine, and norepinephrine, and that surge drives an oxytocin response — the hormone most associated with trust and social bonding.

The practical result is a period of reduced fear reactivity during which a person can approach traumatic memories with a therapist without the usual defensive response taking over. Bird, Modlin and Rucker review the therapeutic rationale for this in trauma-related psychopathology, noting that around half of PTSD cases present with comorbid major depression — a fact that matters later in this comparison.^[4]

This mechanism maps onto the Phase 3 results. In MAPP1, 90 participants with severe PTSD were randomized 1:1 to MDMA-assisted therapy or placebo with identical therapy.^[5] Mean CAPS-5 change was -24.4 for MDMA versus -13.9 for placebo (d=0.91, p<0.0001), and 67% of the MDMA group no longer met PTSD criteria versus 32% on placebo.

MAPP2 replicated this in a larger, more diverse cohort: 104 participants randomized (53 to MDMA-assisted therapy, 51 to placebo with therapy).^[6] Least-squares mean CAPS-5 change was -23.7 for MDMA versus -14.8 for placebo (d=0.7, p<0.001), with 71.2% versus 47.6% no longer meeting diagnostic criteria. Two blinded trials, consistent direction, consistent magnitude.

The limitation is specific and mechanistic. MDMA reduces fear reactivity during the session. It does not, on its own, dismantle the cognitive framework that maintains PTSD between sessions. A person can experience less fear while recalling a memory and still return to the same way of thinking about themselves and what happened.

What Psilocybin Does Differently: Disrupting the Cognitive Loop

Psilocybin's primary target is the 5-HT2A receptor, densely expressed in the frontal cortex. Choi and colleagues review how this maps onto PTSD neurobiology: receptor activation drives increased neural plasticity, and the default mode network — the regions most active during self-referential thought and autobiographical narrative — is temporarily suppressed.^[7]

In PTSD, that self-referential network is where a good deal of the damage lives. A traumatized person's narrative organizes around the trauma: it happened, it defines me, I am permanently changed, it will happen again.

Modlin and colleagues propose a framework for why this matters: PTSD as a maladaptive interpretive framework that is both predetermined and over-determined — a schema so locked in that standard psychotherapy, and even MDMA's fear-reduction window, may not dislodge it.^[8] When the default mode network is disrupted, the dominant narrative loses some of its grip, and a different reading of the same events becomes available.

This is a conceptual framework supported by a clinical narrative, not a tested hypothesis. Modlin's paper is explicit that it is proposing a way of thinking about psilocybin treatment for PTSD. It has not been tested against MDMA, or against a placebo, in a PTSD population.

When MDMA Has the Stronger Case: Fear-Dominant PTSD

The evidence base for MDMA in PTSD is substantially larger and more rigorous. For PTSD in which fear-based symptoms dominate — hyperarousal, avoidance, intrusive fear memories, exaggerated startle — MDMA has direct, replicated, placebo-controlled trial evidence and psilocybin has none.

For patients whose primary obstacle is trust, MDMA's oxytocin response is specifically relevant. Many patients with interpersonal or complex trauma histories cannot reach the state of trust that guided trauma processing requires, and MDMA pharmacologically enables that state during the session.

The MDMA protocol is also well-specified: three MDMA sessions over a 12–18 week course, with preparatory and integration therapy between them, tested in that form across both Phase 3 trials. Both therapists and patients know what to expect.

MDMA's limitations are equally specific. Its cardiovascular effects — elevated heart rate and blood pressure — mean careful screening and monitoring, and exclude some patients with cardiac conditions. And as above, fear reduction does not by itself reach fixed interpretive patterns: for presentations dominated by identity-level damage, chronic shame, or what trauma-focused therapists call "stuck points," MDMA alone may reach a ceiling.

For context on how the Lykos rejection and psilocybin's advancing trials are reshaping this landscape, after Lykos: what psilocybin means for psychedelic PTSD treatment covers the regulatory shift in detail.

Where Psilocybin's Mechanism Plausibly Fits: Three Scenarios

Three scenarios recur in the 2022–2025 literature as places psilocybin's mechanism may suit the presentation. Each is a hypothesis derived from mechanism and adjacent evidence. None has been tested in a controlled PTSD trial, and none has been compared against MDMA.

PTSD with co-occurring depression. The two conditions co-occur in roughly half of PTSD cases.^[4] MDMA-assisted therapy was developed and tested for PTSD symptoms specifically; psilocybin's largest evidence base by far is in depression, where Bahji's pooled estimate was the strongest of the four compounds reviewed.^[1] Miller and Zoladz review the case for extending psilocybin's antidepressant and anxiolytic effects to PTSD, while noting that this remains an inference from adjacent conditions rather than a PTSD finding.^[10]

Patients who cannot take MDMA. MDMA's cardiovascular effects mean it is not suitable for everyone, and Phase 3 protocols screened and monitored for exactly this.^[5] For patients excluded on those grounds, psilocybin is an alternative that is being investigated — though it is worth being clear that this is an argument about MDMA's constraints, not evidence of psilocybin's comparative safety. No study has compared the cardiovascular profiles of the two compounds in a PTSD population.

Trauma rooted in identity and meaning. For trauma that has altered how a person understands themselves, Modlin's schema-disruption framework suggests psilocybin may reach a layer that fear reduction does not.^[8] The nearest empirical anchor is indirect: Khan and colleagues review an open-label study in traumatized AIDS survivors in which psilocybin-assisted psychotherapy reduced PTSD symptoms, attachment anxiety, and demoralization — a different population, an uncontrolled design, and, as their review notes, undertaken when no study had yet investigated psilocybin as a PTSD treatment at all.^[9]

Clinical context

Critical

Neither compound is available as a self-directed treatment

Concern

Both MDMA and psilocybin are administered in these trials at doses and in settings that require medical screening, cardiovascular monitoring, and trained therapist support across preparation, dosing, and integration sessions. MDMA raises heart rate and blood pressure. Psilocybin can produce intense psychological distress during the session, and PTSD populations are specifically vulnerable to trauma resurfacing. Both interact with common psychiatric medications, and Phase 3 protocols required medication washout before dosing.

What the research says

Where these treatments are legally available, they are delivered under authorised-prescriber schemes with screening and monitoring built in. The trial results described in this article were produced inside those structures, and the therapy component is not separable from the drug.

Particularly relevant for: Anyone with a cardiac condition, a personal or family history of psychosis or bipolar disorder, or who is currently taking serotonergic medication faces additional specific risks.

What to do

This article is a summary of published research, not medical advice. Treatment decisions for PTSD should be made with a qualified clinician who knows your history.

Mitchell et al. 2021; Mitchell et al. 2023; McGowan et al. 2025; Nutt et al. 2024

The Regulatory Reality: FDA Rejection, Australian Approval, and What Comes Next

The most consequential event in this field since 2022 was the FDA's August 2024 Complete Response Letter rejecting Lykos Therapeutics' application for MDMA-assisted therapy. The rejection did not turn primarily on efficacy. It cited study design concerns — above all the difficulty of maintaining a blind in psychedelic trials — alongside questions about trial site conduct.

The practical result is that MDMA-assisted therapy has no clear near-term US approval path. Psilocybin does not have one for PTSD either, but its programme is advancing rather than retreating.

Australia offers the most-cited counterexample, and it is routinely overstated. Nutt and colleagues document the TGA's 2023 rescheduling, which took effect on 1 July 2023 and allowed authorised psychiatrists to prescribe both compounds.^[12] But the two approvals are not symmetrical: MDMA was approved for PTSD, and psilocybin only for treatment-resistant depression. Australia is therefore not generating real-world psilocybin PTSD data, because prescribing psilocybin for PTSD is not what was authorised. It is a natural experiment in how a health system absorbs psychedelic therapy — not a head-to-head comparison for PTSD.

For patients following clinical development, psilocybin for PTSD: current clinical trials and preliminary data tracks what is currently underway.

What Patients Experience Differently: A Qualitative Distinction

The mechanistic differences produce qualitatively different experiences that symptom scales do not capture well.

Modlin and colleagues conducted a qualitative study nested inside the same open-label COMP360 trial that McGowan reported, interviewing 21 participants before treatment, the day after dosing, and 12 weeks later.^[11] Four themes emerged, and the most relevant to this comparison is how participants engaged with traumatic material. Unlike standard treatments that require direct confrontation with trauma memories, psilocybin appeared to enable a broader, more indirect engagement — through affective, somatic, and self-transcendent experiences, including moments of perceived unity or dissolution of self.

Two caveats matter. First, this is the same 22-person trial, not independent corroboration: the qualitative study and the safety trial describe one cohort, and both were funded by Compass Pathways, which develops COMP360. Second, qualitative research characterises experience; it does not establish efficacy.

MDMA produces something recognisably different: intense emotional presence, high trust, and the capacity to stay with fear rather than avoid it. Its therapeutic value lies in direct engagement with feared material in a pharmacologically regulated state — immersive in a way psilocybin is not.

That distinction may eventually prove clinically useful. Some patients may be better suited to immersive, emotionally present work; others to a more distanced engagement. For patients who have found exposure-based therapies re-traumatizing, psilocybin's indirect engagement is an appealing hypothesis. It remains a hypothesis. For safety data on psilocybin in PTSD specifically, psilocybin for PTSD: safety and tolerability data covers the tolerability evidence in detail.

The Bottom Line

MDMA-assisted therapy and psilocybin are often discussed as two comparable options for PTSD. They are not at comparable stages. MDMA has two blinded, placebo-controlled Phase 3 trials with consistent effects (d=0.91 and d=0.7) and replicated loss-of-diagnosis rates. Psilocybin has no randomized controlled trial in PTSD at all; its published evidence is small open-label trials without control groups, the largest of which enrolled 22 participants, was designed to assess safety rather than efficacy, and reported no response rate. The mechanisms genuinely differ — MDMA reduces fear reactivity through a monoamine and oxytocin surge, while psilocybin disrupts the default mode network and, on Modlin's framework, may loosen the interpretive schema that maintains PTSD. That difference makes a complementary-roles story plausible, and it is why psilocybin is being investigated for PTSD with comorbid depression, for patients who cannot take MDMA, and for identity-level trauma. But every one of those indications is currently an inference from mechanism and adjacent evidence, not a finding from a controlled PTSD trial. Australia's 2023 rescheduling does not close the gap, because it approved psilocybin only for treatment-resistant depression. The randomized controlled trial that would make this a real comparison has not yet been published.

Frequently Asked Questions

Is psilocybin or MDMA better for combat PTSD?

The evidence does not support a winner for combat PTSD, and the asymmetry is larger than most summaries suggest. MDMA has two blinded Phase 3 RCTs in PTSD generally; psilocybin has no randomized trial in PTSD at all, only small open-label ones without control groups. For combat PTSD dominated by fear symptoms, hyperarousal, and avoidance, MDMA's mechanism matches the presentation and has trial evidence behind it. For combat PTSD with co-occurring moral injury, identity disruption, or treatment-resistant depression, psilocybin's default mode network disruption is a reasonable hypothesis about where it might help — but it is a hypothesis. Neither compound has been tested in a blinded RCT in a specifically military PTSD population, and no trial has compared them directly.

How long does MDMA therapy take compared to psilocybin?

The MDMA-assisted therapy protocol tested in both Phase 3 trials involves three MDMA sessions of roughly 8 hours each, spread over 12–18 weeks, with preparatory and integration therapy sessions between them. The psilocybin PTSD protocol is far less established: McGowan's 2025 trial used a single 25mg dose with preparatory and integration sessions, and measured outcomes at weeks 4 and 12. A single-session model would have real practical advantages for patients with limited access to extended treatment. But one uncontrolled trial does not establish that a single dose is sufficient, and the extended MDMA protocol is part of what was actually tested and shown to work.

What are the risks of MDMA therapy vs. psilocybin for PTSD?

MDMA's main documented risks are cardiovascular — elevated heart rate and blood pressure — which require screening and monitoring and exclude some patients with cardiac conditions. Serotonin syndrome is a risk with certain medication combinations. In psilocybin's one PTSD trial, 117 treatment-emergent adverse events were recorded across 22 participants, with none serious and none causing withdrawal; the most common were headache (50%), nausea (36.4%), crying (27.3%), and fatigue (27.3%). Psilocybin's principal risks are psychological: acute anxiety or confusion during the session, difficult emotional material, and trauma resurfacing, which is a particular concern in PTSD populations. It is important to be clear that no study has directly compared the safety of the two compounds in PTSD patients, so any ranking of their risks is an inference rather than a measured result.

Does psilocybin work for treatment-resistant PTSD?

This has not been established. McGowan's 2025 trial enrolled participants with PTSD and reported a 29.9-point mean CAPS-5 reduction at week 4, but it was open-label with no comparator, so it cannot show that psilocybin caused the improvement. Modlin's 2025 framework specifically addresses treatment-resistant presentations, arguing that when standard therapies have reduced fear reactivity but the underlying schema remains intact, psilocybin's mechanism is theoretically distinct from what has already been tried. That is a well-argued rationale for running the trial, not a result from one. Randomized trials in PTSD are underway; until they report, the honest answer is that the evidence is preliminary and uncontrolled.

Why is MDMA approved in Australia but not the US?

Australia's Therapeutic Goods Administration rescheduled both compounds in 2023, taking effect 1 July 2023: MDMA for PTSD and psilocybin for treatment-resistant depression, prescribable only by psychiatrists authorised under the TGA's Authorised Prescriber Scheme. The FDA declined to approve MDMA-assisted therapy in August 2024, citing trial methodology rather than efficacy — principally the difficulty of maintaining blinding in psychedelic trials, plus concerns about conduct at some trial sites. Two regulators applied different standards to substantially the same evidence and reached different conclusions. One frequent misreading is worth correcting: Australia did not approve psilocybin for PTSD, so its rollout produces no real-world evidence on psilocybin as a PTSD treatment.

Sources & References

1. 1RTHM-02055·Bahji, Anees et al. (2025). “Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis..” Journal of psychoactive drugs.Study breakdown →PubMed →↩
2. 2RTHM-00941·McGowan, Niall M et al. (2025). “Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
3. 3RTHM-01449·Varker, Tracey et al. (2021). “Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin..” Journal of psychoactive drugs.Study breakdown →PubMed →↩
4. 4RTHM-01328·Bird, Catherine I V et al. (2021). “Psilocybin and MDMA for the treatment of trauma-related psychopathology..” International review of psychiatry (Abingdon.Study breakdown →PubMed →↩
5. 5RTHM-01407·Mitchell, Jennifer M et al. (2021). “MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study..” Nature medicine.Study breakdown →PubMed →↩
6. 6RTHM-01755·Mitchell, Jennifer M et al. (2023). “MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial..” Nature medicine.Study breakdown →PubMed →↩
7. 7RTHM-01874·Choi, Charles et al. (2024). “Mechanisms of psilocybin on the treatment of posttraumatic stress disorder..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
8. 8RTHM-00946·Modlin, Nadav Liam et al. (2025). “Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework..” Therapeutic advances in psychopharmacology.Study breakdown →PubMed →↩
9. 9RTHM-00770·Khan, Amanda J et al. (2022). “Psilocybin for Trauma-Related Disorders..” Current topics in behavioral neurosciences.Study breakdown →PubMed →↩
10. 10RTHM-02149·Miller, Claire E et al. (2025). “Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder..” The Journal of pharmacology and experimental therapeutics.Study breakdown →PubMed →↩
11. 11RTHM-02152·Modlin, Nadav Liam et al. (2025). “Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment..” EClinicalMedicine.Study breakdown →PubMed →↩
12. 12RTHM-00898·Nutt, David J et al. (2024). “The Australia story: Current status and future challenges for the clinical applications of psychedelics..” British journal of pharmacology.Study breakdown →PubMed →↩